EUVIMEDEUVIMED entdecken
Crossref

Computational Identification of FDA‐Approved Drugs as STAT3 Dimerization Inhibitors for Therapeutic Applications

Muhammad Yasir, Jinyoung Park, Jongseon Choe, Wanjoo Chun

ChemistrySelect · 2026-01 · 11 (2)

DOI: 10.1002/slct.202502991 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 12.01.2026. Verfasst von Muhammad Yasir und 3 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Korea Basic Science Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dysregulation of STAT3 signaling is implicated in the progression of numerous diseases, including cancer and autoimmune disorders, making it a critical target for therapeutic intervention. Given its multifaceted involvement in multiple disease pathways, targeting STAT3 presents a broad therapeutic opportunity. This study employs an integrative computational approach combining pharmacophore modeling, molecular docking, molecular dynamics (MD) simulations, and free energy calculation to identify and evaluate potential STAT3 dimerization inhibitors. FDA approved drug library was used as it offers significant advantages, including established safety profiles, known pharmacokinetics, and faster clinical translation. The library was screened using a receptor–ligand interaction pharmacophore model, followed by molecular docking and MD simulations to assess stability and interaction persistence within the STAT3 dimerization site. gmxMMPBSA analysis further validated the binding affinities of top‐ranked compounds, providing detailed insights into their energetic profiles. Among the compounds, Tavalisse, ADP, and Vipivotide tetraxetan emerged as the most promising candidates, demonstrating exceptional binding stability, favorable interaction energies, and significant pharmacophore match scores. Additionally, the confirmatory triplicate runs of these compounds further emphasize the stable binding against the SH2 domain of STAT3. Moreover, this study also highlights the critical interaction profile of the screened compounds, forming hydrogen bonds, hydrophobic interactions, and maintaining ligand‐receptor complexes. These findings offer a robust framework for the development of selective and potent STAT3 dimerization inhibitors, paving the way for therapeutic advancements against STAT3‐mediated disorders.

Förderung

  • Korea Basic Science Institute

Zitieren

APA

Yasir, M., Park, J., Choe, J., & Chun, W. (2026). Computational Identification of FDA‐Approved Drugs as STAT3 Dimerization Inhibitors for Therapeutic Applications. ChemistrySelect, 11(2). https://doi.org/10.1002/slct.202502991

Vancouver

Yasir M, Park J, Choe J, Chun W. Computational Identification of FDA‐Approved Drugs as STAT3 Dimerization Inhibitors for Therapeutic Applications. ChemistrySelect. 2026;11(2). doi:10.1002/slct.202502991

BibTeX
@article{Yasir2026,
  author = {Yasir, Muhammad and Park, Jinyoung and Choe, Jongseon and Chun, Wanjoo},
  title = {Computational Identification of FDA‐Approved Drugs as STAT3 Dimerization Inhibitors for Therapeutic Applications},
  journal = {ChemistrySelect},
  year = {2026},
  volume = {11},
  number = {2},
  doi = {10.1002/slct.202502991}
}
Kostenlos starten →